ライフサイエンスコーパス: poor

1 cal outcome after nerve damage is frequently poor.

2 ingle-factors treatments was also relatively poor.

3 However, expression was unstable and poor.

4 patients with cardiogenic shock has remained poor.

5 te such descriptors of rainfall is generally poor.

6 echanistic understanding of NET formation is poor.

7 ents with higher circulating soluble AXL had poor 1-year outcomes after ICH onset, suggesting that th

8 Presenting visual acuity was generally poor (20/50 to >20/200 in 27%; 20/200 or worse in 56%).

9 lative to more obvious epidemic drivers, and poor ability to differentiate between the effects of pop

10 tion carriers were high language dysfluency, poor ability to organize material, and low self-monitori

11 Functional impairment was a composite of poor academic performance (defined as at least 1 standar

12 However, due to poor access and affordability, screening and diagnosis f

13 es, smoke, indoor dampness, cockroaches, and poor access to health care.

14 ess of makerspaces ameliorates the otherwise poor accessibility and scalability of microfluidic proto

15 have the 10th transmembrane domain show very poor activity.

16 engthy and onerous, and hence complicated by poor adherence leading to drug resistance and disease re

17 th persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or b

18 ps among these events are debated because of poor age constraints and contradictory stratigraphic cor

19 ur calculated velocities are in increasingly poor agreement with those of the lower mantle at depths

20 hat poor environmental quality, particularly poor air quality, was associated with increased mortalit

21 ome Americans whereas it has stagnated among poor Americans and even declined in some demographic gro

22 an eclipsed stacking motif with the electron-poor ammonium methyl groups occupying the electron-rich

23 d in most women, long-term renal outcome was poor; among the 14 women, four had CKD stage 1-4, five h

24 bonding to the next incoming monomer exhibit poor amyloid formation and act as potent inhibitors in t

25 ow-cost, rapid, and simple features, but the poor analytical sensitivity of LFA restricts its applica

26 ensity multi-cellular recording methods with poor anatomical correlations.

27 Poor ancient DNA preservation in these regions challenge

28 to a diet that is energy dense but nutrient poor and increase risk of developing obesity, cardiovasc

29 , which predict more animal consumption in N-poor and more productive environments respectively, fail

30 Historical outcomes for this group were poor and often involved prolonged chemotherapy; on NWTS-

31 PEL prognosis is poor and patients barely survive >6 months even followin

32 ere accelerated by important increases among poor and rural mothers and children.

33 butable risk to quantify the contribution of poor and rural populations to national trends.

34 The prognosis is poor and the five-year survival rate ranges from 20% (OS

35 Residence in urban or poor areas and non-Hispanic black race/ethnicity were al

36 the ability to arylate neutral and electron-poor arenes-substrates that do not react at all in the i

37 asthma treatment, these patients experience poor asthma control and face the greatest risk of asthma

38 In contrast, poor asthma control typically presents with a diurnal va

39 orizing levels of knowledge and practices as poor, average, and good.

40 The prognosis of EAC remains poor because it is usually diagnosed late, and many effo

41 technical challenges such as low potency or poor biophysical properties.

42 e from nonshockable-turned-shockable OHCA is poor but not invariably fatal.

43 that mixtures of BINOL and B(OPh)3 were very poor catalysts compared to the same mixtures with VANOL

44 re documented transfers, and in cohorts with poor CD4 count documentation, whereas higher patient loa

45 imately disseminating to colonize the purine-poor central nervous system.

46 period is reasonably well-known, relatively poor chronological control has precluded precise alignme

47 arker cleaved LC3 expression correlates with poor clinical outcome in ESCC.

48 s with colorectal cancer was associated with poor clinical outcome, irrespective of HIF-1 In addition

49 ects of AURKA overexpression associated with poor clinical outcomes have been attributed to increased

50 that elevated expression of GADD45B confers poor clinical outcomes in most human cancers.

51 ma; also, its low expression correlates with poor clinical outcomes in renal cell carcinoma.

52 n critically ill patients is associated with poor clinical outcomes.

53 iastolic ventricular function resulting in a poor clinical prognosis.

54 ted with poor functional outcome (P = 0.04), poor cognitive outcome (P = 0.03), post-stroke anxiety (

55 compromised integrity of coated pellets and poor content uniformity.

56 ation at near-cognate UUG codons and AUGs in poor context.

57 ellent coherence but limited photon flux due poor conversion efficiency.

58 ingitis (ABM) in adults residing in resource-poor countries is associated with mortality rates >50%.

59 ntinue for long-term maintenance in resource-poor countries of AFP surveillance as a platform for sur

60 a neglected issue, particularly in resource-poor countries.

61 rovide high charge storage capacity but with poor cyclic stability due to structural damage occurring

62 Poor delivery efficiency continues to hamper the effecti

63 petiolata) throughout New England driven by poor demographic performance in warmer climates.

64 t were skewed away from MPECs with resultant poor development of circulating and lung-resident memory

65 velopmental trajectories and are at risk for poor developmental outcomes.

66 polymerase chain reaction (PCR) in blood had poor diagnostic accuracy for diagnosing pneumococcal pne

67 ake (EI) later in the day is associated with poor diet quality and obesity.

68 T2DM arises largely from obesity, poor diet, and lack of exercise, but it also involves ge

69 because colonising species can be relatively poor dispersers with specific niche requirements.

70 Weakly stabilizing or electron-poor donor groups provide better yields of the ABL produ

71 c DC, whereas thymic or splenic B cells were poor donors.

72 erformance of such logic circuits was rather poor due to the difficulty of controlling spin waves in

73 rtimox and benznidazole, two drugs that have poor efficacy in the chronic phase and are rather toxic.

74 However, poor efficiencies in gene transfer and undesirable safet

75 These results suggest that poor environmental quality, particularly poor air qualit

76 duced in women whose CYP2D6 genotypes confer poor enzyme function.

77 orter OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multipl

78 le used to support testing and the generally poor evidence on which to base this rationale.

79 educed glucose utilization in the muscle and poor exercise performance.

80 Consistent with poor feto-placental perfusion, Egfl7 knockout resulted i

81 methodology for detecting consolidation, but poor for other infiltrates despite attempts at a rigorou

82 orecast method and less prone to producing a poor forecast.

83 d higher accumulation of biomass in nutrient-poor forests compared to nutrient-richer forests.

84 at 1 year was independently associated with poor functional outcome (P = 0.04), poor cognitive outco

85 upport a model in which EAP deficits lead to poor functional outcome via impaired cognition and incre

86 ear post-LT transplant costs were older age, poor functional status (KPS 10%-40%), living donor LT, p

87 ubstituents and with both electron-rich and -poor functionality displayed at different sites of the a

88 hway that most significantly correlated with poor gemcitabine response in pancreatic cancer patients.

89 umor location (48 patients) or the patient's poor general condition (10 patients).

90 d in 1990 to 1999 were more likely to report poor general health (11.2% vs. 13.7%; P < 0.001) and can

91 pressure, physical inactivity, smoking, and poor glucose control) are associated with incident HF in

92 jectories for those with good, moderate, and poor glycemic control at baseline, while supermarket gai

93 pediatric patients with T1D after one-year's poor glycemic control.

94 on, as may cross-border movements of camels, poor hand hygiene, and overnight hospital stays with res

95 dvantaged households face increased risks of poor health in adulthood, suggesting that inequalities i

96 provide a risk marker for vulnerability and poor health outcomes.

97 er underweight or obese were associated with poor health status.

98 ngagement in HIV care but is associated with poor HIV treatment outcomes after release.

99 approach to defray TB-related costs only in poor households with a confirmed TB diagnosis.

100 itive cash transfer approach to increase all poor households' income may have broad benefits by reduc

101 helminth infestations, bare footedness, and poor housing, and still there is a high prevalence of al

102 ofile, containing sites that are enriched or poor in NP association.

103 The adherence tended to be poor in patients with short duration of disease, smoking

104 When liposomes poor in sphingomyelin/cholesterol or mimicking the lipid

105 national or subnational health services is a poor indicator of financial protection.

106 t reduced reticulon-1 is responsible for the poor inherent ability of macrophages to respond to chemo

107 ynthesized, and although the former are very poor inhibitors, the latter compounds are highly effecti

108 dy is the first to show associations between poor inhibitory control and amphetamine reward sensitivi

109 iated with older age at diagnosis, male sex, poor initial levodopa treatment response, and postural i

110 Subjects were classified as having poor, intermediate, or ideal cardiovascular health based

111 and solid stress within tumors contribute to poor intratumoral distribution of nanomedicine.

112 have resulted in pancreas underdigestion and poor islet recovery but improved islet function.

113 n the first week (UNOS-DGF), associates with poor kidney transplant outcomes.

114 density at catalyst interface, resulting in poor kinetics and negative catalytic performance.

115 corresponding sequence alignment is usually poor, leading to poor performance for the recognition of

116 al decomposition into solute-rich and solute-poor liquid phases, nucleation of amorphous nanoclusters

117 producing significant patient mortality and poor long-term outcomes.

118 rdiac abnormalities that are associated with poor long-term survival.

119 nventional treat-to-target trial designs had poor (<5%) statistical power to detect the HTEs, despite

120 an increase the risk of FGR, one of which is poor maternal diet.

121 that the commonly employed strategy yields a poor measure of true resolution since it does not accoun

122 xo adduct becomes inert under tension due to poor mechanochemical coupling.

123 exposed to interpersonal violence exhibited poor memory of contexts paired with angry faces and atyp

124 Exposure to bullying is associated with poor mental health.

125 rties, low ductility at room temperature and poor microstructural stability at elevated temperatures

126 lysis of AnxA2-deficient muscle we find that poor myofiber repair due to the lack of AnxA2 does not r

127 activity grew best on organic P, whereas the poor N2 fixer and the two non-N2 fixers with high AM col

128 Having exited poor neighborhoods was associated with lower systolic bl

129 In cells grown in poor nitrogen medium, the nitrogen permease reactivator

130 natal growth faltering persisted, leading to poor nutritional status at 24 months (length-for-age Z s

131 The tested TCA intermediates were poor or moderate KDM5B inhibitors, except for oxaloaceta

132 on of the oral microbiome were observed with poor oral hygiene, tobacco smoking, and oral cancer.

133 riables tested were strongly associated with poor outcome (CSF culture positivity, CSF white blood ce

134 t patients, approximately 1 in 3 still had a poor outcome 1 year after TAVR.

135 n of ARF in the nucleolus is associated with poor outcome and attenuated response to chemotherapy.

136 Whether poor outcome associated with cannabis use is mediated th

137 between reduced brain tissue oxygenation and poor outcome following severe traumatic brain injury has

138 ociated with a more aggressive phenotype and poor outcome of patients, although more specific signatu

139 Odds ratio (OR) for predicting poor outcome or standardized mean difference (SMD) of th

140 as developed after variables associated with poor outcome were identified at multivariate analysis (K

141 pecificity and sensitivity for prediction of poor outcome were independent of age, sex, and initial r

142 d elevated levels of HP1gamma in PCa predict poor outcome.

143 arge B-cell lymphoma (DLBCL) associated with poor outcomes after standard chemoimmunotherapy.

144 nth retention rates seldom exceeding 50% and poor outcomes following dropout, we must explore innovat

145 sation registry to identify risk factors for poor outcomes in adult patients with community-acquired

146 Metabolic acidosis is associated with poor outcomes in CKD.

147 and glycemic variability are associated with poor outcomes in critically ill patients.

148 High expression of CCAR2 correlates with poor outcomes in many human tumor types such as squamous

149 ical risk factors and are more predictive of poor outcomes than the rate of development of hyponatrem

150 geted temperature management toward good and poor outcomes, along with other recognized predictors.

151 dney injury is common and is associated with poor outcomes, including increased mortality, among crit

152 bjects have more rapid cognitive decline and poor outcomes.

153 calcitrant to treatment, and associated with poor outcomes.

154 abolism but largely lack treatments and have poor outcomes.

155 markers could improve risk stratification of poor outcomes.

156 s with infection who are at elevated risk of poor outcomes.

157 nd that MICU1 overexpression correlates with poor overall survival (OS).

158 entify the risk factors for determination of poor overall survival after RFA.

159 cell transplant (SCT, p = 0.0005) predicted poor overall survival.

160 ance BCSC properties and are correlated with poor overall survival.

161 and this genetic deletion is associated with poor overall survival.

162 with increased risk of technical failure and poor pancreas allograft outcomes.

163 vity are decreased versus normal kidney; and poor patient outcome associates with lower expression of

164 ative miR-375 expression was associated with poor patient prognosis.

165 rimary colorectal cancer was associated with poor patient survival.

166 n MM and that its expression correlates with poor patients' outcome.

167 quence alignment is usually poor, leading to poor performance for the recognition of similarity.

168 biocrude production simultaneously; each had poor performance in at least one function (i.e., <25th p

169 come was neurosensory impairment, defined as poor performance in one or more domains.

170 The poor performance of single-agent melphalan in this setti

171 ver, they present some limitations including poor performance, short-lifetimes, and expensive ion-sel

172 are older, have altered mobility, experience poor perfusion, or who are receiving a vasopressor infus

173 nesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts h

174 iRNA) is hampered by siRNA's comprehensively poor pharmacokinetic properties, which necessitate molec

175 along with the coexistence of Li-rich and Li-poor phases are broadly observed on partially delithiate

176 tes that BiOI, previously considered to be a poor photocatalyst, is promising for photovoltaics.

177 ith potentially reactive chemical motifs and poor physicochemical properties are published as selecti

178 xiety; 3) optimistic health expectations; 4) poor planning for medical setbacks; and 5) disruptive ca

179 ty, particularly in the areas of challenging poor practice, and recognising, responding to and disclo

180 Moreover, the poor predictive power of the KDPI for adult donors appea

181 berculosis infection (LTBI) are limited by a poor predictive value for identifying people at the high

182 Yet focal crop pollen foraging was a poor predictor of pesticide risk, which was driven prima

183 Accordingly, poor presentation of a mutation across patients was corr

184 ins great challenge due to the low activity, poor product selectivity and stability of electrocatalys

185 action toward the synthesis of very electron-poor products, making these more readily accessible.

186 othelioma is a highly aggressive cancer with poor prognosis and few treatment options following progr

187 east cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but the

188 WS: n = 99 patients), TF was associated with poor prognosis and increased risk of blood vessel infilt

189 with low MFN2 expression are associated with poor prognosis as compared to patients with high MFN2 ex

190 , is re-expressed by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often ass

191 tastasis, pre-metastatic niche formation and poor prognosis in breast cancer patients.

192 ation (CRT) therapy and carries a relatively poor prognosis in comparison with HPV-positive disease,

193 nd other malignancies and is associated with poor prognosis in leukemia patients.

194 ad4 expression significantly correlated with poor prognosis in LUAD but not in SCC.

195 malize metabolic aberrations responsible for poor prognosis in ovarian cancer.

196 on and therapy intensification abrogates the poor prognosis of adult ETP-ALL.

197 ptionally repressed in cancers and signifies poor prognosis of breast cancer patients.

198 esistance, immune evasion, and ultimately to poor prognosis of cancer patients.

199 c peptide (NT-proBNP) concentration predicts poor prognosis of non-CNS cancer patients.

200 eased protein level has been associated with poor prognosis of several types of cancers.

201 icity seems to be acceptable considering the poor prognosis of the eligible patients.

202 ed with basal-like breast cancer (BLBC) with poor prognosis owing to its role in promoting epithelial

203 cative of chromothripsis and associated with poor prognosis per se and not merely by association with

204 TCF genetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic

205 Gastric cancer (GC) has a poor prognosis with wide variation in survival rates acr

206 nts with acute myeloid leukemia (AML) have a poor prognosis, and innovative maintenance therapy could

207 Renal cell carcinoma (RCC) is a cancer with poor prognosis, and the 5-year survival rate of patients

208 osis (MALA), a severe medical condition with poor prognosis, especially in individuals with renal dys

209 nosquamous lung tumours, which are extremely poor prognosis, may result from cellular plasticity.

210 r to oesophageal adenocarcinoma, which has a poor prognosis.

211 ma (PDAC) is an aggressive malignancy with a poor prognosis.

212 ny human solid tumors and is associated with poor prognosis.

213 at low miR-383 expression is associated with poor prognosis.

214 with end-stage liver disease and portends a poor prognosis.

215 is found in tumor samples from patients with poor prognosis.

216 sociated with more aggressive phenotypes and poor prognosis.

217 neo)adjuvant chemotherapy fails to improve a poor prognosis.

218 noma (NEC - neuroednocrine carcinoma) with a poor prognosis.

219 AP4 was increased in human CRC and predicted poor prognosis.

220 gy, and therapy response and usually predict poor prognosis.

221 ssociated with an advanced tumor state and a poor prognosis.

222 act, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape.

223 n the presence of excessive blasts and other poor prognostic factors, hypomethylating agents are the

224 elial cancer, most of whom were elderly, had poor prognostic factors, or had serious comorbidities.

225 nd comorbidities of chronic diseases exhibit poor proliferative and migratory capabilities, which imp

226 This restraint might be because of the poor proliferative capacity of aged donor hepatocytes or

227 ion during ICU rounds at our institution was poor, prone to omissions and inaccuracies, yet largely u

228 Thematic analyses demonstrated: 1) poor quality of life for patients; 2) surrogate stress a

229 e aneuploidies are lethal or associated with poor quality of life, a view that is now being challenge

230 ory" with nonprogressive liver disease but a poor quality of life.

231 luding memory impairments that contribute to poor quality of life.

232 ave coped with years of disease activity and poor quality of life.

233 However, the poor reach of LHWs in accessing newborn infants at birth

234 w that motion processing deficits are due to poor reading experience.

235 clinical cohorts, wherein it associated with poor recurrence-free survival.

236 n expression from DNA sequence alone remains poor, reflecting our limited understanding of cis-regula

237 rate, heart muscle, at least in mammals, has poor regenerative potential.

238 tation drives GC content lower in already GC-poor regions, and using our precise context-dependent mu

239 e association studies (GWAS), there has been poor replication of gene expression studies in chronic o

240 This study highlights the poor representation of Arctic photosynthesis in TBMs, an

241 y, current methods suffer from invasiveness, poor resolution and low specificity.

242 that prevents discontinuation; predictors of poor response could not be reliably identified.

243 ation disorders, helps with interpreting the poor response reported in the few investigated HB patien

244 Poor response to DEB-TACE (SD or DP) was present in 86%

245 a need to develop better markers to predict poor response to omalizumab therapy and alternative trea

246 pectrometry because of, in most cases, their poor responsivities toward nuclear magnetic resonance, u

247 otential explanations are possible including poor risk standardization, more research is needed.

248 lated ADI (ADI-PEG20) in relapsed/refractory/poor-risk acute myeloid leukemia (AML) was evaluated in

249 ite, nonseminoma histology, intermediate- or poor-risk disease at the time of GCT diagnosis, and huma

250 nt predictors of severe anemia were malaria, poor sanitation, and underweight.

251 However, poor scaling often renders direct ab initio calculations

252 kend bedtime and wake up time, and also with poor school performance.

253 However, outcomes remain poor secondary to corneal melting, scarring, and perfora

254 preoperatively identifiable risk factors of poor seizure outcome.

255 have significantly higher odds of reporting poor self-rated health and impaired functional capacity

256 It is commonly believed that humans have a poor sense of smell compared to other mammalian species.

257 ate to severe childhood diarrhea in resource-poor settings.

258 injury (AKI) in children is associated with poor short-term and long-term health outcomes; however,

259 (all colonies performed poorly at the flower poor site).

260 , 59%, 49%, and 18% of participants reported poor social integration, economic problems, worrying abo

261 Children residing in poor socioeconomic conditions, as in Zanzibar, are heavi

262 displays high productivity under drought and poor soil conditions, it is susceptible to disease, post

263 ke and plant biomass production on phosphate-poor soils.

264 eral issues should be addressed, including a poor solubility of fatty acid and a substantial loss in

265 r ibrutinib relapse have been reported to be poor, specific strategies are needed for this patient po

266 good as it detected multiple samples but had poor stability and low sensitivity.

267 ost amino acids, the imino acid proline is a poor substrate for protein synthesis.

268 However, one-site linear DNA is a poor substrate, supporting a mechanism where CglI comple

269 tained ribose derivatives are, however, very poor substrates for further installation of the nucleoba

270 Specifically, electron-rich and electron-poor subunits were introduced in the conjugated backbone

271 erapy, there is a high incidence of CLAD and poor survival after AMR.

272 r distal resection margin is associated with poor survival and higher recurrence, studies looking at

273 Poor survival and vascular engraftment rates of transpla

274 e also discriminated between patients with a poor survival at 180 days (34% survived) and a good surv

275 metrial carcinoma progression and ultimately poor survival from disease.

276 e 1 (TAK1; MAP3K7), which is associated with poor survival in HCC and interleukin-6 (IL6) expression.

277 ated from metastases and was associated with poor survival of colon cancer patients.

278 KB1 expression significantly correlates with poor survival outcome in breast cancer.

279 Poor survival was preceded by an adverse change in panel

280 Factors independently associated with poor survival were: being from an African countries othe

281 tween high MCAM levels in patient tumors and poor survival, in two different Ewing Sarcoma clinical c

282 tory disease or early relapse have extremely poor survival.

283 We tested whether SCFAs contribute to poor TB control in a longitudinal cohort of ART-treated

284 tems referring to four factors: futile care, poor teamwork, deceptive communication, and ethical misc

285 ore and investigate test stimuli, leading to poor test performance that was only slightly improved by

286 An OPRS score of 3.0 (scale of 1 [poor] to 5 [excellent]) indicated proficiency.

287 lates with longer coding and UTR regions and poor translatability.

288 One reason for such poor translation from drug candidate to successful use i

289 Ventilation >7 days was associated with poor transplant suitability (P = .04).

290 es, COPD was not found to be associated with poor transplant suitability (P = .22).

291 g for risk factors typically associated with poor treatment outcomes.

292 for either FTD or NCL, in part because of a poor understanding of how mutations in genes such as GRN

293 Disease heterogeneity and poor understanding of pathogenic mechanisms hampers the

294 jor clinical challenge and may relate to the poor understanding of the molecular mechanisms involved.

295 gy of alternating electron rich and electron poor units facilitates a visible light fusion reaction i

296 s associated health benefits are hindered by poor urban infrastructure.

297 Enucleation may be required due to poor vision and inability to adequately monitor for tumo

298 Poor visual outcome was defined as BCVA of worse than 20

299 masked-sentence recognition is particularly poor when the masker is composed of two competing talker

300 t interventions toward adolescents and rural poor women.